2401 4TH AVE., SEATTLE, WA
Secures $1.5 Million Non-Dilutive Research Grant from the Andy Hill Care Fund to Advance APVO451, a Nectin-4-Targeted Trispecific Immunotherapy for Solid Tumors
Launch Strategic Collaboration for Radiopharmaceutical Therapeutic Development, Includes Strategic Equity Investment at Closing
Provides a 1Q26 Business Update; RAINIER on Track for 2026 Completion and Phase 2 Dose Selection
Reports 87% Clinical Benefit and 81% Remission in 31 Evaluable Frontline AML Patients Through Cohort 5, Substantially Outperforming Benchmark; RAINIER on Track for 2026 Completion and Phase 2 Dose Selection
Delivers Compelling 86% Clinical Benefit Rate and No CRS as Evaluable AML Patient Data increases by Nearly 50%
Stockholder Vote Results from Aptevo Therapeutics Special Meeting
Announces Executive Leadership Transitions to Support Next Phase of Growth
Secures $60 Million Equity Line of Credit to Support Multispecific Portfolio Advancement, Increase Strategic Optionality
Q1
Q3
Q2
FY 2023
Effectiveness Notice
Prospectus filed pursuant to Rule 424(b)(4)
S-1
Definitive Proxy Statement
PRE 14A
Schedule 13G - Ownership Report
Initial Statement of Beneficial Ownership
Amended Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
Correspondence
Submission Upload